Article info

Download PDFPDF

Canakinumab for Treatment of Adult-Onset Still’s Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial

Authors

  1. Correspondence to Claudia Kedor, Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin 10117, Germany; claudia.kedor{at}charite.de
View Full Text

Citation

Kedor C, Listing J, Zernicke J, et al
Canakinumab for Treatment of Adult-Onset Still’s Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial

Publication history

  • Received February 20, 2020
  • Revised April 22, 2020
  • Accepted April 22, 2020
  • First published May 13, 2020.
Online issue publication 
July 13, 2020

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.